Mazdutide vs Tirzepatide
An approved-in-China dual agonist against the most effective FDA-approved weight-management drug available — real efficacy data on both sides, but very different regulatory maturity.
Short answer
The clearest difference is regulatory. Tirzepatide is FDA-approved, and mazdutide is still investigational in the US. Tirzepatide fits a reader who wants an FDA-approved product, while mazdutide is marketed for weight loss and type 2 diabetes. On the evidence, mazdutide has human clinical data and tirzepatide has approval-level evidence.
Mazdutide
A GLP-1/glucagon dual agonist approved in China for both obesity and type-2 diabetes, with real Phase 2/3 efficacy data — but still investigational in the US, where no approval application has cleared.
Full Mazdutide evidence reviewTirzepatide
Zepbound / Mounjaro
Up to ~21% mean weight loss in SURMOUNT-1 — the most effective FDA-approved weight-management drug.
Full Tirzepatide evidence reviewMazdutide vs Tirzepatide: head to head
- FDA status / approved use
Mazdutide
Approved in China in 2025 for weight management and type 2 diabetes; not approved in the USTirzepatide
Prescription drug sold as Mounjaro and Zepbound- Marketed for
Mazdutide
Weight loss, type-2 diabetesTirzepatide
Weight loss, type-2 diabetes- Outcome areas
Mazdutide
Weight loss / appetite; Blood sugar / insulin sensitivityTirzepatide
Weight loss / appetite; Blood sugar / insulin sensitivity- Evidence grade
Mazdutide
Clinical dataTirzepatide
FDA-approved- How it works
Mazdutide
Activates both GLP-1 and glucagon receptors, curbing appetite and mobilizing liver fatTirzepatide
Dual agonist of the GLP-1 and GIP receptors- Route and dosing
Mazdutide
Injection, once weeklyTirzepatide
Subcutaneous, once weekly (Zepbound label); maintenance 5, 10 or 15 mg once weekly (10 or 15 mg for sleep apnea)- Headline human result
Mazdutide
About −14.0% mean weight loss on 6 mg at 48 weeks vs roughly flat placebo in the phase 3 GLORY-1 trialTirzepatide
20.9% mean weight loss vs 3.1% on placebo at 72 weeks (SURMOUNT-1, 15 mg weekly)- Strongest evidence
Mazdutide
Phase 2 obesity RCT, 2023Mazdutide evidence reviewPubMed 38092790Tirzepatide
SURMOUNT-1, NEJM 2022Tirzepatide evidence reviewPubMed 35658024- Key safety signal
Mazdutide
Gastrointestinal events most common, mostly mild to moderate; no long-term cardiovascular outcome dataTirzepatide
Gastrointestinal side effects, the same class as semaglutide- How it is obtained
Mazdutide
Legitimately available only inside clinical trials; vials sold online are gray-market research chemicalsTirzepatide
Prescription. Eligible manufacturer self-pay offers for Zepbound: $299–$449 per 4 weeks; dose, refill timing and program terms apply. Introductory prices can differ and regular prices may be higher.Zepbound cost breakdown
| Mazdutide | Tirzepatide | |
|---|---|---|
| FDA status / approved use | Approved in China in 2025 for weight management and type 2 diabetes; not approved in the US | Prescription drug sold as Mounjaro and Zepbound |
| Marketed for | Weight loss, type-2 diabetes | Weight loss, type-2 diabetes |
| Outcome areas | Weight loss / appetite; Blood sugar / insulin sensitivity | Weight loss / appetite; Blood sugar / insulin sensitivity |
| Evidence grade | Clinical data | FDA-approved |
| How it works | Activates both GLP-1 and glucagon receptors, curbing appetite and mobilizing liver fat | Dual agonist of the GLP-1 and GIP receptors |
| Route and dosing | Injection, once weekly | Subcutaneous, once weekly (Zepbound label); maintenance 5, 10 or 15 mg once weekly (10 or 15 mg for sleep apnea) |
| Headline human result | About −14.0% mean weight loss on 6 mg at 48 weeks vs roughly flat placebo in the phase 3 GLORY-1 trial | 20.9% mean weight loss vs 3.1% on placebo at 72 weeks (SURMOUNT-1, 15 mg weekly) |
| Strongest evidence | Phase 2 obesity RCT, 2023Mazdutide evidence reviewPubMed 38092790 | SURMOUNT-1, NEJM 2022Tirzepatide evidence reviewPubMed 35658024 |
| Key safety signal | Gastrointestinal events most common, mostly mild to moderate; no long-term cardiovascular outcome data | Gastrointestinal side effects, the same class as semaglutide |
| How it is obtained | Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals | Prescription. Eligible manufacturer self-pay offers for Zepbound: $299–$449 per 4 weeks; dose, refill timing and program terms apply. Introductory prices can differ and regular prices may be higher.Zepbound cost breakdown |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Tirzepatide is the benchmark: FDA-approved, up to ~21% mean weight loss in SURMOUNT-1, the strongest approved option available today. Mazdutide is a genuine GLP-1/glucagon dual agonist with real Phase 2/3 efficacy data and an actual approval — in China, for both obesity and type-2 diabetes — but it remains fully investigational in the US with no cleared application. They've never been compared head-to-head.
Mazdutide fits if
You're tracking the pipeline of dual-mechanism agonists reaching approval anywhere in the world, not looking for a US prescription.
Tirzepatide fits if
You want the option with FDA approval and the deepest published efficacy record available today.
Mazdutide vs Tirzepatide: common questions
- Is tirzepatide FDA-approved but mazdutide not?
- Yes. Tirzepatide is a prescription drug sold as Mounjaro and Zepbound. Mazdutide is approved in China in 2025 for weight management and type 2 diabetes; not approved in the US.
- Which has stronger human evidence, mazdutide or tirzepatide?
- Tirzepatide. It has approval-level evidence (key source: SURMOUNT-1, NEJM 2022), while mazdutide has human clinical data (key source: Phase 2 obesity RCT, 2023).
- What are the main safety concerns with mazdutide and tirzepatide?
- With mazdutide, gastrointestinal events are most common, mostly mild to moderate; no long-term cardiovascular outcome data. For tirzepatide, watch for gastrointestinal side effects, the same class as semaglutide.
Key studies behind each
Mazdutide
- Ji L, Jiang H, Cheng Z, et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. PubMed 38092790
- Zhang B, Cheng Z, Chen J, et al. (2024). Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care. PubMed 37943529
- Ji L, Jiang H, Bi Y, et al. (GLORY-1 Investigators) (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. PubMed 40421736
- Jiang H, Pang S, Zhang Y, et al. (2022). A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. PubMed 35750681
Tirzepatide
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024
- Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PubMed 34170647
- Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PubMed 40353578
The full evidence reviews
- Mazdutide: the GLP-1/glucagon dual agonist approved in China
A once-weekly GLP-1 and glucagon dual agonist from Innovent, licensed from Eli Lilly. What the GLORY-1 Phase 3 data show — and exactly where it is and isn't approved.
Updated August 2026
- Tirzepatide vs semaglutide for weight loss: what the trials actually support
SURMOUNT-5 found 20.2% versus 13.7% average weight loss. What that direct comparison supports, which doses it tested, and why newer formulations need separate evidence.
Updated October 2026